mHealth Mood Management Tool (Actify) to Improve Population-Level Smoking Cessation
Trial Summary
What is the purpose of this trial?
This phase I trial investigates a new smartphone application (called Actify) for improving population-level smoking cessation and mood management. Actify delivers behavioral activation therapy for depression as part of a smoking cessation intervention and will be compared to another smoking cessation smartphone application that is based on current clinical practice guidelines. Participants will be randomly assigned to receive one of two smartphone applications and accompanying text notifications to help with quitting smoking and improved mood.
Research Team
Jaimee Heffner
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Actify (Behavioural Intervention)
- Current Standard Care app (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Fred Hutchinson Cancer Research Center
Lead Sponsor
Dr. Nancy Davidson
Fred Hutchinson Cancer Research Center
Chief Medical Officer since 2020
MD from Harvard Medical School
Dr. Thomas J. Lynch Jr.
Fred Hutchinson Cancer Research Center
Chief Executive Officer since 2020
MD from Yale University, BA from Yale College
Fred Hutchinson Cancer Center
Lead Sponsor
Dr. W. Thomas Purcell
Fred Hutchinson Cancer Center
Chief Medical Officer since 2022
MD from Emory University School of Medicine, MBA from University of Chicago
Dr. Thomas J. Lynch Jr.
Fred Hutchinson Cancer Center
Chief Executive Officer since 2020
MD from Yale School of Medicine
National Institute on Drug Abuse (NIDA)
Collaborator
Dr. Nora Volkow
National Institute on Drug Abuse (NIDA)
Chief Executive Officer since 2003
MD from National Autonomous University of Mexico
Dr. Nora Volkow
National Institute on Drug Abuse (NIDA)
Chief Medical Officer since 2003
MD from National Autonomous University of Mexico